The purpose of this study is to identify one or more doses of BMS-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis C virus (Genotypes 1 and 4).
Tablets, Oral, 200 mg, Twice Daily, 48 weeks
Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
Tablets, Oral, 0 mg, twice daily, 48 weeks
Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
Tablets, Oral, 0 mg, twice daily 24 weeks
Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
Buenos Aires, Buenos Aires, Argentina
Ciudad de Buenos Aires, Buenos Aires, Argentina
Prov. Buenos Aires, Buenos Aires, Argentina
Prov de Santa Fe, Santa Fe Province, Argentina